Who Paid My Doc
P0 ASCVD Olpasiran Prescreening for CVOT
Research payments
$960,278
Through program year 2024, $960,278 in research payments was reported against P0 ASCVD Olpasiran Prescreening for CVOT, across 79 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $27,025 | 6 |
| 2023 | Research | $811,438 | 51 |
| 2022 | Research | $121,814 | 22 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Nishant Shah Raleigh, NC Named on 2 payments
- Thomas Knickelbine Minneapolis, MN Named on 2 payments
- Ferris George Saint Augustine, FL Named on 2 payments
- Ian Neeland Westlake, OH Named on 2 payments
- John McGinty Richmond, IN Named on 1 payment
- Alan Wiseman Bangor, ME Named on 1 payment
- Lan Luo Ocala, FL Named on 1 payment
- Abbas Shehadeh West Orange, NJ Named on 1 payment
- Samer Nakhle Las Vegas, NV Named on 1 payment
- Sandeep Khurana Grandville, MI Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.